Risk of Gastrointestinal Bleeding in Asian Patients Receiving Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2024 Aug 21

PMID 39165614

Authors

Alejandro Bimbo Diaz

Jeremy Chow

Fan Kee Hoo

Gary Lee Chin Keong

Narayanaswamy Venketasubramanian

Nannette Rey

Gregorio Rogelio

Radhika Mehta

Affiliations

Soon will be listed here.

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.

References

Carnicelli A, Hong H, Connolly S, Eikelboom J, Giugliano R, Morrow D . Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022; 145(4):242-255. PMC: 8800560. DOI: 10.1161/CIRCULATIONAHA.121.056355. View

Yamashita T, Koretsune Y, Nagao T, Shiosakai K . Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses. J Arrhythm. 2020; 36(3):395-405. PMC: 7279995. DOI: 10.1002/joa3.12332. View

Hung Y, Hu Y, Liu C, Lin Y, Chang S, Lo L . Risk and predictors of subsequent cancers of patients with newly-diagnosed atrial fibrillation - A nationwide population-based study. Int J Cardiol. 2019; 296:81-86. DOI: 10.1016/j.ijcard.2019.08.021. View

Savelieva I, Camm A . Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol. 2013; 37(1):32-47. PMC: 6649642. DOI: 10.1002/clc.22204. View

Choi E, Lin W, Hwang G, Kirchhof P, De Caterina R, Chen C . Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. J Clin Med. 2021; 10(22). PMC: 8623093. DOI: 10.3390/jcm10225337. View

Chao T, Joung B, Takahashi Y, Lim T, Choi E, Chan Y . 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm. 2021; 37(6):1389-1426. PMC: 8637102. DOI: 10.1002/joa3.12652. View

Chao T, Chiang C, Lin Y, Chang S, Lo L, Hu Y . Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. Circulation. 2018; 138(14):1485-1487. DOI: 10.1161/CIRCULATIONAHA.118.036046. View

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

Lee S, Kwon S, Choi E, Jung J, Han K, Oh S . Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovasc Drugs Ther. 2021; 36(4):679-689. DOI: 10.1007/s10557-021-07170-6. View

10.

Ruff C, Giugliano R, Antman E, Crugnale S, Bocanegra T, Mercuri M . Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial.... Am Heart J. 2010; 160(4):635-41. DOI: 10.1016/j.ahj.2010.06.042. View

11.

Schulman S, Kearon C . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-4. DOI: 10.1111/j.1538-7836.2005.01204.x. View

12.

Chao T, Hong K, Lee B, De Caterina R, Kirchhof P, Reimitz P . Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J Chin Med Assoc. 2021; 84(5):485-490. DOI: 10.1097/JCMA.0000000000000516. View

13.

Ruff C, Giugliano R, Braunwald E, Morrow D, Murphy S, Kuder J . Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385(9984):2288-95. DOI: 10.1016/S0140-6736(14)61943-7. View

14.

Chao T, Unverdorben M, Kirchhof P, Koretsune Y, Yamashita T, Crozier R . Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program. J Clin Med. 2023; 12(5). PMC: 10003604. DOI: 10.3390/jcm12051870. View

15.

Liao J, Chan Y, Kuo L, Tsai C, Lim S, Chao T . Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?. Kardiol Pol. 2022; 80(2):128-136. DOI: 10.33963/KP.a2022.0046. View

16.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F . New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012; 59(16):1413-25. DOI: 10.1016/j.jacc.2012.02.008. View

17.

Shen A, Yao J, Brar S, Jorgensen M, Chen W . Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50(4):309-15. DOI: 10.1016/j.jacc.2007.01.098. View

18.

Milling Jr T, Spyropoulos A . Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. Am J Emerg Med. 2016; 34(11S):19-25. PMC: 5678962. DOI: 10.1016/j.ajem.2016.09.049. View

19.

Ogilvie I, Newton N, Welner S, Cowell W, Lip G . Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123(7):638-645.e4. DOI: 10.1016/j.amjmed.2009.11.025. View

20.

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View